VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Learn more about Beyond Air Inc's (XAIR) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Medical Equipment, Supplies & Distribution stock meets your investment needs.
Jenna Brashear
Financial Summary
Share Statistics
XAIR
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$3.8
$337.2
3%
Shares Out (Mil)
0.7
41.9
3%
Institutional Ownership
80.7%
77.8%
50%
Float (Mil)
0.7
34.7
2%
Beta
0.22
0.85
13%
Avg Daily Volume (000s)
14
278
19%
Price Change (52-week)
(91.2%)
58.7%
4%
Growth
XAIR
Industry Median
Percentile (All Stocks)
Sales (5yr)
53.6%
11.8%
96%
Net Income (5yr)
(7.7%)
(5.8%)
31%
EPS (5yr)
30.9%
11.4%
82
Dividends (5yr)
0.0%
0.0%
0%
Cash Flow (5yr)
(39.3%)
(16.3%)
12%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
na
na
na
Current EPS
($11.333)
($75.467)
($37.400)
Month Ago EPS
na
na
na
# Rev Up
1
1
na
# Rev Down
1
0
na
Three Months Ago EPS
($9.000)
($81.000)
na
Year/Year Chg
(26.8%)
(5.8%)
(49.3%)
Financials
XAIR
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
$8
$152
8%
Net Income (TTM) (Mil)
($33)
($10)
20%
EPS (TTM)
($80.109)
($0.500)
1%
Operating Cash Flow (TTM) (Mil)
($18)
($2)
15%
Net Cash Flow (TTM) (Mil)
$8
$1
55%
Long-Term Debt (Q1) (Mil)
$23
$22
34%
Enterprise Value (Q1) (Mil)
$16
$304
10%
Valuation
XAIR
Industry Median
Percentile (All Stocks)
P/B
0.51
2.80
9%
P/E
na
31.1
na
Dividend Yield
0.0%
0.0%
0%
PEG (5yr hist)
na
1.9
na
Ratios
XAIR
Industry Median
Percentile (All Stocks)
Gross Margin
3.3%
59.1%
5%
Net Margin
(433.0%)
(7.3%)
2%
ROA
(101.6%)
(13.7%)
5%
ROE
(337.4%)
(15.8%)
2%
Liabilities to Assets
82.5%
44.7%
77%
F-Score
5
4
51%
Beyond Air, Inc. did not pass any screens on 7/31/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors